Close menu




February 12th, 2021 | 14:11 CET

Steinhoff, Osino Resources, Sibanye Stillwater- Bargain hunters beware!

  • Investments
Photo credits: pixabay.com

When is a stock cheap? The obvious criterion of a low stock price can sometimes be misleading. For value investors, a stock is cheap when the stock price and intrinsic value are too far apart. Still, other investors "buy" the trend and bet that the movement will continue when the price rises. All approaches have one thing in common: the profit lies in the purchase. We will make you winners!

time to read: 2 minutes | Author: Carsten Mainitz
ISIN: CA68828L1004 , NL0011375019 , ZAE000259701

Table of contents:


    STEINHOFF INTERNATIONAL HOLDINGS NV - next Monday will be exciting!

    The price of the penny stock has doubled since the beginning of the year. The rise occurred, in particular in the wake of speculation that the protracted legal disputes resulting from the massive accounting scandal from 2017 could now be coming to an end.
    However, investors will find out next Monday whether there may still be signs of a setback. A group of investors has asked the competent court in Amsterdam to appoint a new expert to clarify various issues, citing Dutch insolvency law. It is currently impossible to estimate what impact this latest round of legal penalties will have. The Group has at least strongly resisted this step.

    Thus, a lot is going on at Steinhoff - also behind the scenes. Goldman Sachs has secured a 2.8% block of shares recently. There was also an update on the development of the listed South African subsidiary Pepkor, in which Steinhoff holds around 68%. As a result, Steinhoff's stake is currently worth around EUR 2.2 billion. At first glance, the parent company's market capitalization appears very moderate at around EUR 500 million. But the lawsuits of around USD 8 billion floating in the air put the whole thing into perspective. Steinhoff's settlement offer is around USD 1 billion. So it remains very exciting!

    OSINO RESOURCES CORP - important milestones in the next months

    The Canadian gold explorer released further encouraging drill results from the Twin Hills Central Project and the new Clouds Zone in late January. These results show continuing mineralization and near-surface mineralization at the Clouds zone. In addition, the Company announced that it plans to carry out an extensive drilling program of 75,000 meters in the current year. The Canadians plan to release a resource estimate before the end of the first quarter and a prospective economic assessment (PEA) no later than the end of June.

    Osino Resources has focused on acquiring and developing gold projects in Namibia and holds 23 exclusive prospecting licenses covering an area of 6,577 sq km. Namibia is mining-friendly and is considered one of the most stable jurisdictions on the continent, both politically and socially.

    The share has been trading in a corridor of around CAD 1.20 to CAD 1.45 over the last three months. At the latest with the hard facts the Company plans to publish at the end of Q1 and Q2, the share should break out on the upside. With a current market value of CAD 125 million, the Company is by no means overvalued given the project's quality and size.

    SIBANYE STILLWATER LIMITED - 2020 Earnings Exceed Market Expectations

    Sibanye-Stillwater is the largest gold producer in Africa and is among the TOP 3 platinum and palladium producers globally. Last week, the Group published its preliminary figures for the past fiscal year, exceeding market expectations.

    Significantly higher precious metal prices and a weak rand made profits bubble up. According to preliminary calculations, the South African Company achieved a profit for the year of USD 1.75 billion to USD 1.82 billion, corresponding to earnings per share of between USD 0.64 and USD 0.67. Analysts, on average, had expected consolidated revenue of USD 1.7 billion. By comparison, business performance was still very problematic in 2019, resulting in a profit of only USD 4 million.

    Experts expect profits to continue to rise significantly to around USD 3 billion in the current fiscal year. Based on these forecasts, the 2021 P/E ratio is about 4.7, a very moderate valuation level. The stock has more than quadrupled since its low last spring. Nevertheless, analysts see further upside potential of 14% on average in the short term.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 29th, 2023 | 07:00 CEST

    Defence Therapeutics, Schott Pharma, Allianz Group: Focus on Innovation, Growth and Portfolio Optimization

    • Biotechnology
    • Pharma
    • Investments

    According to a recent study, biotech company Defence Therapeutics achieves twice the immune response of conventional mRNA therapies with its Accum® mRNA technology. That translates to fewer side effects and a more effective treatment. According to Precedence Research, the market size for mRNA therapeutics is projected to reach approximately USD 137.59 billion by 2032. It is expected to grow at a CAGR of 13.2% from 2023 to 2032. In order to inject these active ingredients, precision-fit medical vials are required, and Schott Pharma is ensuring this with their IPO launched on the German stock exchange this week, which could bring a valuation of around EUR 4 billion. The Allianz Group, on the other hand, is focusing on consolidation, selling its business in the Middle East and thus flushing around EUR 210 million cash into its coffers.

    Read

    Commented by André Will-Laudien on September 26th, 2023 | 07:45 CEST

    Artificial Intelligence in Sellout! Nvidia, Defense Metals, ARM Holdings - Nothing works without rare earths!

    • Mining
    • RareEarths
    • AI
    • chips
    • Investments

    After long bull market movements, the stock market usually tends to rotate sectors, or the market enters a general consolidation. In the former case, investors can profit by reallocating their assets while exploring new investment opportunities. In the latter case, all stocks come down, and the capital market generally suffers from a change in sentiment and corrects recently exaggerated valuations. In the case of the new megatrend of Artificial Intelligence (AI), the stock market seems to sense a great need for correction. As if by magic, the blockbuster stock Nvidia rose by 250% in just 9 months. However, it has already retraced nearly 20% from its peak. Where do the opportunities lie for investors?

    Read

    Commented by André Will-Laudien on September 22nd, 2023 | 07:20 CEST

    Recalculation! These are the bare figures: TUI, Saturn Oil + Gas, Deutsche Bank - Buy prices non-stop!

    • Mining
    • Oil
    • travel
    • Investments
    • Banking

    Companies do not always have good figures in their baggage. Analysts listen very carefully to the words of those in charge. Often, it is only a minor sentence that changes entire valuations. TUI is slowly approaching pre-COVID figures. Saturn Oil & Gas must backtrack slightly because of substantial forest fires in Alberta, and Deutsche Bank aims to finalize the Postbank project in 2023. All three stocks offer good buying opportunities because the long-term prospects are quite convincing.

    Read